Gyre Therapeutics (GYRE) Income from Non-Controlling Interests (2012 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Income from Non-Controlling Interests of -$1.2 million for Q1 2026, down 212.64% year-over-year from $1.0 million in Q1 2025, and down 426.89% quarter-over-quarter from $357000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Income from Non-Controlling Interests (2012 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Income from Non-Controlling Interests for 8 consecutive years, with -$1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests fell 212.64% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at $2.6 million (down 40.4% YoY), while the FY2025 annual figure was $4.9 million, down 16.51% from the prior year.
- Income from Non-Controlling Interests slipped to -$1.2 million in Q1 2026 per GYRE's latest filing, from $357000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $3.5 million in Q3 2023 and bottomed at -$1.2 million in Q1 2026.
- Historically, Income from Non-Controlling Interests has averaged $1.3 million across 4 years, with a median of $1.1 million in 2025.
- Annual changes were most pronounced in 2024 — Income from Non-Controlling Interests soared 2203.45% — and 2026, when it plunged 212.64%.
- Gyre Therapeutics' Income from Non-Controlling Interests stood at $29000.0 in 2023, then jumped by 2203.45% to $668000.0 in 2024, then sank by 46.56% to $357000.0 in 2025, then sank by 426.89% to -$1.2 million in 2026.
- Business Quant data shows GYRE's Income from Non-Controlling Interests at -$1.2 million in Q1 2026, $357000.0 in Q4 2025, and $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 63.60 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | -3.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.67 Mn |
| Mar 31, 2026 | -1.17 Mn |
| Dec 31, 2025 | 357,000.00 |
| Sep 30, 2025 | 2.33 Mn |
| Jun 30, 2025 | 1.13 Mn |
| Mar 31, 2025 | 1.04 Mn |
| Dec 31, 2024 | 668,000.00 |
| Sep 30, 2024 | 1.73 Mn |
| Jun 30, 2024 | 1.01 Mn |
| Mar 31, 2024 | 2.40 Mn |
| Dec 31, 2023 | 29,000.00 |
| Sep 30, 2023 | 3.53 Mn |
| Jun 30, 2023 | 1.92 Mn |
| Mar 31, 2023 | 1.97 Mn |
| Jun 30, 2015 | -12,000.00 |
| Mar 31, 2015 | 19,000.00 |
| Dec 31, 2014 | -51,000.00 |
| Sep 30, 2014 | -55,000.00 |
| Jun 30, 2014 | 44,000.00 |
| Mar 31, 2014 | -21,000.00 |